Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma

BACKGROUND: Rituximab (R) in combination with DHAP is a widely accepted salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). A common adverse effect of this protocol is renal toxicity which may result in treatment discontinuation. Assuming that a lower sing...

Descripción completa

Detalles Bibliográficos
Autores principales: Lisenko, K., McClanahan, F., Schöning, T., Schwarzbich, M. A., Cremer, M., Dittrich, T., Ho, A. D., Witzens-Harig, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828891/
https://www.ncbi.nlm.nih.gov/pubmed/27067641
http://dx.doi.org/10.1186/s12885-016-2289-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828891/
https://www.ncbi.nlm.nih.gov/pubmed/27067641
http://dx.doi.org/10.1186/s12885-016-2289-y

Ejemplares similares